[EN] NOVEL ARYL-CYANOGUANIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS D'ARYL-CYANOGUANIDINE
申请人:BAYER PHARMA AG
公开号:WO2016166186A1
公开(公告)日:2016-10-20
The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.
本发明涉及蛋白酰赖氨酸N-甲基转移酶SMYD2(SET和MYND结构域含有蛋白2)抑制剂,特别是通式(I)的SMYD2抑制剂取代氰基胍-吡唑啉,其中R1,R2,R3,R4和R5具有如下所述和定义的含义,以及包含根据本发明的化合物的制药组合物以及它们在高增殖性疾病,特别是癌症,以及肿瘤性疾病的预防和治疗中的预防和治疗用途。本发明还涉及SMYD2抑制剂用于良性增生,动脉粥样硬化性疾病,败血症,自身免疫性疾病,血管疾病,病毒感染,神经退行性疾病,炎症性疾病,动脉粥样硬化性疾病和男性生育控制。